Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zoledronic acid

Drug Profile

Zoledronic acid

Alternative Names: Aclasta; AK-156; CGP-42446A; Reclast; ZOL-446; zoledronate; Zometa

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Asahi Kasei Pharma Corp; Novartis; UNICANCER
  • Class Antineoplastics; Bisphosphonates; Calcium regulators; Imidazoles; Osteoporosis therapies; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors; Geranyltranstransferase inhibitors; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Bone metastases; Corticosteroid-induced osteoporosis; Fracture; Male osteoporosis; Malignant hypercalcaemia; Mesothelioma; Multiple myeloma; Osteitis deformans; Postmenopausal osteoporosis
  • Registered Osteoporosis
  • Phase II Breast cancer
  • Discontinued Osteogenesis imperfecta; Osteosarcoma; Rheumatoid arthritis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 05 Mar 2018 Novartis Pharmaceuticals completes a phase III trial in Corticosteroid-induced osteoporosis (In adolescents, In children) Australia, Canada, Finland, Romania, Italy, Russia, South Africa, Germany, Hungary, Belgium, Poland and the UK (IV) (EudraCT2008-001252-52) (NCT00799266)
  • 07 Nov 2017 Asahi Kasei Pharma Corporation completes a clinical trial for Osteoporosis in Japan (UMIN000026507)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top